{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:14:31Z","timestamp":1790342071701,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T00:00:00Z","timestamp":1432944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00345-015-1598-0","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T07:54:53Z","timestamp":1432886093000},"page":"173-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation"],"prefix":"10.1007","volume":"34","author":[{"given":"Rianne J. M.","family":"Lammers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C. M.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Rodriguez Faba","family":"Rodriguez Faba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim P. J.","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,30]]},"reference":[{"issue":"2","key":"1598_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69\u201390","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1598_CR2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639\u2013653. doi: 10.1016\/j.eururo.2013.06.003","journal-title":"Eur Urol"},{"issue":"6","key":"1598_CR3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","volume":"186","author":"M Brausi","year":"2011","unstructured":"Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Bohle A (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186(6):2158\u20132167. doi: 10.1016\/j.juro.2011.07.076","journal-title":"J Urol"},{"issue":"3","key":"1598_CR4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477","journal-title":"Eur Urol"},{"issue":"3 Pt 2","key":"1598_CR5","first-page":"929","volume":"153","author":"PD Vegt","year":"1995","unstructured":"Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP (1995) A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153(3 Pt 2):929\u2013933","journal-title":"J Urol"},{"issue":"5","key":"1598_CR6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","volume":"53","author":"K Hendricksen","year":"2008","unstructured":"Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA (2008) Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53(5):984\u2013991","journal-title":"Eur Urol"},{"key":"1598_CR7","author":"RJ Lammers","year":"2012","unstructured":"Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA (2012) Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol. doi: 10.1200\/jco.2011.39.2936","journal-title":"J Clin Oncol"},{"issue":"5","key":"1598_CR8","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203","journal-title":"J Urol"},{"issue":"1","key":"1598_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(17)35397-1","volume":"150","author":"LA Kiemeney","year":"1993","unstructured":"Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150(1):60\u201364","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"1598_CR10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","volume":"164","author":"F Millan-Rodriguez","year":"2000","unstructured":"Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1):680\u2013684","journal-title":"J Urol"},{"issue":"5","key":"1598_CR11","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1097\/01.ju.0000154696.48217.75","volume":"173","author":"SF Shariat","year":"2005","unstructured":"Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173(5):1518\u20131525. doi: 10.1097\/01.ju.0000154696.48217.75","journal-title":"J Urol"},{"issue":"3","key":"1598_CR12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3346\/jkms.2008.23.3.428","volume":"23","author":"SJ Hong","year":"2008","unstructured":"Hong SJ, Cho KS, Han M, Rhew HY, Kim CS, Ryu SB, Sul CK, Chung MK, Park TC, Kim HJ (2008) Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci 23(3):428\u2013433. doi: 10.3346\/jkms.2008.23.3.428","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1598_CR13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10147-010-0049-6","volume":"15","author":"T Yamada","year":"2010","unstructured":"Yamada T, Tsuchiya K, Kato S, Kamei S, Taniguchi M, Takeuchi T, Yamamoto N, Ehara H, Deguchi T (2010) A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients. Int J Clin Oncol 15(3):271\u2013279. doi: 10.1007\/s10147-010-0049-6","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"1598_CR14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/jcp.2010.079764","volume":"63","author":"CC Pan","year":"2010","unstructured":"Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM (2010) Constructing prognostic model incorporating the 2004 WHO\/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol 63(10):910\u2013915. doi: 10.1136\/jcp.2010.079764","journal-title":"J Clin Pathol"},{"issue":"3","key":"1598_CR15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000328635","volume":"87","author":"N Shapur","year":"2011","unstructured":"Shapur N, Pode D, Katz R, Shapiro A, Yutkin V, Pizov G, Appelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON (2011) Predicting the risk of high-grade bladder cancer using noninvasive data. Urol Int 87(3):319\u2013324. doi: 10.1159\/000328635","journal-title":"Urol Int"},{"key":"1598_CR16","author":"AM Kamat","year":"2014","unstructured":"Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Bohle A, Colombel M, Palou J (2014) Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. doi: 10.1016\/j.juro.2014.02.2573","journal-title":"J Urol"},{"issue":"10","key":"1598_CR17","doi-asserted-by":"crossref","first-page":"e47199","DOI":"10.1371\/journal.pone.0047199","volume":"7","author":"Z Chen","year":"2012","unstructured":"Chen Z, Ding W, Xu K, Tan J, Sun C, Gou Y, Tong S, Xia G, Fang Z, Ding Q (2012) The 1973 WHO classification is more suitable than the 2004 WHO classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS ONE 7(10):e47199. doi: 10.1371\/journal.pone.0047199","journal-title":"PLoS ONE"},{"key":"1598_CR18","unstructured":"Sylvester RJ (2012) The confusing world of prognostic models and their clinical use. Nijmegen, the Netherlands"},{"issue":"6","key":"1598_CR19","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178(6):2314\u20132330","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-015-1598-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-015-1598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-015-1598-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T19:44:53Z","timestamp":1566762293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-015-1598-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,30]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1007\/s00345-015-1598-0","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,30]]}}}